TOKYO -- Japan's Eisai is planning ways to get its new Alzheimer's drug lecanemab to low-income patients in emerging economies, tapping sustainability-linked loans as early as this fiscal year.
Pharmaceuticals
Eisai eyes low-cost supplies of Alzheimer's drug in SE Asia, India
Sustainable loans considered for FDA-approved lecanemab
Elderly people in Singapore: Eisai wants to expand its patient support program for its new Alzheimer's drug in places like Southeast Asia and India. © Reuters
Read Next
.jpg?width=178&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms&format=auto&height=100)
Latest on Pharmaceuticals
